Research programme: ultra-long acting therapeutics - Allergan/Lyndra

Drug Profile

Research programme: ultra-long acting therapeutics - Allergan/Lyndra

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan; Lyndra
  • Class Antidementias; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 14 Sep 2017 Lyndra and Allergen agree to develop ultra-long-acting therapeutics for Alzheimer’s disease in USA
  • 07 Sep 2017 Early research in Alzheimer's disease in USA (PO)
  • 13 Apr 2017 Lyndra plans a phase I trial for Alzheimer's disease in USA by end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top